All In Biotech

Drug Trial Radar · NCT02275910

Phase 1 Study of E7090 in Subjects With Solid Tumor

A Phase 1 Study of E7090 in Subjects With Solid Tumor

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

40

Actual

Start

Oct 28, 2014

Primary completion

Sep 3, 2021

Study completion Sep 3, 2021

Sponsor

Lead sponsor
Eisai Co., Ltd.Eisai
Sponsor type
Industry
First posted
Oct 27, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1 study of E7090 in subjects with advanced solid tumors. This study will be conducted in 2 parts: 1. Part 1 will be the dose escalation portion of this study to determine the maximum tolerated dose in subjects with solid tumors, and 2. Part 2 will comprise cohort expansions to further characterize the safety and tolerability of E7090 and to assess preliminary efficacy of E7090 in subjects with solid tumors characterized by genetic abnormalities in FGF/FGFR pathway.

Conditions

  • Tumors

Interventions

  • E7090Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: Cycle 0 (Cycle length= 7 days) up to Cycle 1 (Cycle length= 28 days)
  2. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: From the start of study drug administration up to 2 year 9 months

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Eisai Trial Site #1

    Chiba, Japan

  • Eisai Trial Site #1

    Fukuoka, Japan

  • Eisai Trial Site #1

    Kyoto, Japan

  • Eisai Trial Site #1

    Osaka, Japan

  • Eisai Trial Site #2

    Osaka, Japan

  • Eisai Trial Site #3

    Osaka, Japan

  • Eisai Trial Site #1

    Nagoya, Aichi-ken, Japan

  • Eisai Trial Site #1

    Kashiwa, Chiba, Japan

  • Eisai Trial Site #1

    Matsuyama, Ehime, Japan

  • Eisai Trial Site #1

    Sapporo, Hokkaido, Japan

  • Eisai Trial Site #1

    Amagasaki, Hyōgo, Japan

  • Eisai Trial Site #1

    Tsukuba, Ibaraki, Japan

  • Eisai Trial Site #1

    Kawasaki, Kanagawa, Japan

  • Eisai Trial Site #1

    Yokohama, Kanagawa, Japan

  • Eisai Trial Site #1

    Chuo-ku, Niigata, Japan

  • Eisai Trial Site #1

    Kitaadachi, Saitama, Japan

  • Eisai Trial Site #1

    Chuo-Ku, Tokyo, Japan

  • Eisai Trial Site #1

    Koto-ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.